Fig. 2. PFK158 treatment prevents glycolysis in MPM by inhibiting active PFKFB3.

MPM cells evidently increased glucose uptake, LDH activity, intracellular ATP, and phospho-PFKFB3 (S⁴⁶¹) level, which is inhibited by PFK158 treatment. a Fluorescence images of glucose uptake using 2-NBDG in H28 and EMMeso cells. LDH activity (b) and intracellular ATP (c) were measured in H28, H226, H2052, and EMMeso cells in the presence and absence of PFK158 (0–20 μM), where *P < 0.05, **P < 0.05 and ^@P < 0.0001. All experiments were conducted in eight replicates and for at least two times. Data are shown as mean ± SD for eight replicates per cell line. d A dose-dependent decrease in the level of active PFKFB3 [phospho-PFKFB3 (S⁴⁶¹)] after PFK158 treatment